Key 2026 clinical milestones: The recurrent cSCC pivotal trial is nearing completion with last patient treatments expected imminently and topline data planned for H2 2026, while a GBM pilot safety ...
Taysha Gene Therapies (TSHA) reported a net loss of $109.0 million for the full year ending December 31, 2025, translating to a loss of $0.34 per share. This marks an increase from the $89.3 million ...
Our CVIS (Cardiovascular Information Management System) is a unique software solution that empowers you to improve the clinical and financial performance of your cardiology department. Clinical ...
Epic has been reasonably successful in some of the UK’s bigger NHS Trusts such as Greater Manchester, and Guy’s and St Thomas’. Credit: chrisdorney / Shutterstock.com. In early March 2026, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results